Last reviewed · How we verify
Rajaie Cardiovascular Medical and Research Center — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| intermediate dose Enoxaparin/ unfractionated heparin | intermediate dose Enoxaparin/ unfractionated heparin | phase 3 | Low molecular weight heparin | Antithrombin | Cardiovascular | |
| Six percent hydroxy ethyl starch 130/0.4 | Six percent hydroxy ethyl starch 130/0.4 | phase 3 | Synthetic colloid / Volume expander | Cardiovascular / Critical Care |
Therapeutic area mix
- Cardiovascular · 1
- Cardiovascular / Critical Care · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aalborg University Hospital · 1 shared drug class
- China International Neuroscience Institution · 1 shared drug class
- Queen Mary University of London · 1 shared drug class
- VarmX B.V. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Rajaie Cardiovascular Medical and Research Center:
- Rajaie Cardiovascular Medical and Research Center pipeline updates — RSS
- Rajaie Cardiovascular Medical and Research Center pipeline updates — Atom
- Rajaie Cardiovascular Medical and Research Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Rajaie Cardiovascular Medical and Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rajaie-cardiovascular-medical-and-research-center. Accessed 2026-05-17.